NEUROCRINE BIOSCIENCES INC (NBIX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US64125C1099
NEUROCRINE BIOSCIENCES INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.86 bn USD |
| Gross profit | 2.81 bn USD |
| Operating income | 619.10 m USD |
| EBIT | 705.40 m USD |
| Net income | 478.60 m USD |
| Diluted EPS – continuing operations | 4.67 USD |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
More stocks
- Pinnacle Financial Partners, Inc. (PNFP)
- STERLING INFRASTRUCTURE, INC. (STRL)
- Masco (MAS)
- Inner Mongolia BaoTou Steel Union Co Ltd (600010.SS)
- Sichuan Biokin Pharmaceutical Co. Ltd. A (688506.SS)
- SOUTH32 Ltd (S32.AX)
- Rocket Companies, Inc. (RKT)
- Bureau Veritas SA (BVI.PA)
- Jbs NV (JBS)
- Sekisui House Ltd (1928.T)
- Datang International Power Generation Co Ltd Class A (601991.SS)
- Betsson AB (BETS B.ST)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.